EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Fatty Liver Index and Differential Glycemic Responses to Ipragliflozin Versus Sitagliptin Over 52 Weeks: An Exploratory Post Hoc Analysis of the Niigata Ipragliflozin and Sitagliptin With Metformin (N‐ ISM ) Study

Masaru Kitazawa iD, Takashi Katagiri, Hiromi Suzuki, Mayuko Yamada, Mariko Hatta, Hiroki Takizawa, Koshiro Murai, Takaaki Sato, Yasuhiro Matsubayashi iD, Takaho Yamada, Shiro Tanaka, Hirohito Sone iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71211 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Masaru Kitazawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver, Glucosides, Hypoglycemic Agents. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To explore whether fatty liver index (FLI) stratification is associated with differential glycemic responses to sodium‐glucose co‐transporter‐2 (SGLT2) versus dipeptidyl peptidase‐4 (DPP‐4) inhibitors as second‐line therapy in type 2 diabetes without established atherosclerotic cardiovascular disease (ASCVD). Materials and Methods In this exploratory post hoc analysis of a previous 52‐week randomised trial of ipragliflozin versus sitagliptin added to metformin in Japanese patients with type 2 diabetes, 91 patients were stratified by median FLI into low (< 51; n = 44) and high (≥ 51; n = 47) groups. The outcome was the 52‐week change in glycated haemoglobin A1c (HbA1c). The treatment‐by‐FLI interaction was tested by baseline‐HbA1c‐adjusted analysis of covariance; FLI was also modelled continuously and parallel analyses used body mass index (BMI) and alanine aminotransferase (ALT).

Results

The baseline‐HbA1c‐adjusted treatment‐by‐FLI interaction was significant at 52 weeks ( p = 0.013): ipragliflozin was associated with a greater HbA1c reduction than sitagliptin in the high FLI group (−0.41%, 95% confidence interval −0.77, −0.06; p = 0.023), with no significant difference in the low FLI group (+0.24%; p = 0.194). The interaction was also significant with FLI modelled continuously ( p = 0.013) and in mixed‐model and multiple‐imputation sensitivity analyses ( p = 0.010 and 0.003). BMI and ALT showed similar significant interactions ( p = 0.028 and 0.032), favouring ipragliflozin in the high‐value subgroup. FLI provided the clearest signal but was not the only effect modifier.

Conclusions

FLI‐based stratification was associated with differential glycemic responses to ipragliflozin versus sitagliptin. These findings are hypothesis‐generating, given the small, complete‐case sample and the sample‐derived cut‐off. Prospective studies are warranted before FLI can inform antidiabetic drug selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fatty LiverGlucosidesHypoglycemic AgentsMetforminSitagliptin PhosphateThiophenesAgedFemaleHumansMaleMiddle AgedBlood GlucoseDipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationGlycated HemoglobinSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeTreatment Effect Heterogeneity

Stichwörter der Autor:innen

DPP‐4 inhibitorSGLT2 inhibitorfatty liver indextreatment effect heterogeneitytreatment stratificationtype 2 diabetes

Substanzen

Blood GlucoseDipeptidyl-Peptidase IV InhibitorsGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsipragliflozinMetforminSitagliptin PhosphateSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
  • Kashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan.
  • Nagaoka Red Cross Hospital, Nagaoka, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Masaru Kitazawa, Yasuhiro Matsubayashi, Hirohito Sone

Förderung

  • Astellas Pharma

Zitieren

APA

Kitazawa, M., Katagiri, T., Suzuki, H., Yamada, M., Hatta, M., Takizawa, H., Murai, K., Sato, T., Matsubayashi, Y., Yamada, T., Tanaka, S., & Sone, H. (2026). Fatty Liver Index and Differential Glycemic Responses to Ipragliflozin Versus Sitagliptin Over 52 Weeks: An Exploratory Post Hoc Analysis of the Niigata Ipragliflozin and Sitagliptin With Metformin (N‐ ISM ) Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71211

Vancouver

Kitazawa M, Katagiri T, Suzuki H, Yamada M, Hatta M, Takizawa H, et al. Fatty Liver Index and Differential Glycemic Responses to Ipragliflozin Versus Sitagliptin Over 52 Weeks: An Exploratory Post Hoc Analysis of the Niigata Ipragliflozin and Sitagliptin With Metformin (N‐ ISM ) Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71211

BibTeX
@article{Kitazawa2026,
  author = {Kitazawa, Masaru and Katagiri, Takashi and Suzuki, Hiromi and Yamada, Mayuko and Hatta, Mariko and Takizawa, Hiroki and Murai, Koshiro and Sato, Takaaki and Matsubayashi, Yasuhiro and Yamada, Takaho and Tanaka, Shiro and Sone, Hirohito},
  title = {Fatty Liver Index and Differential Glycemic Responses to Ipragliflozin Versus Sitagliptin Over 52 Weeks: An Exploratory Post Hoc Analysis of the Niigata Ipragliflozin and Sitagliptin With Metformin (N‐ ISM ) Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71211}
}
Kostenlos starten →